Roth Capital Initiates Coverage On Helius Medical Tech with Buy Rating, Announces Price Target of $5
Roth Capital analyst Jonathan Aschoff initiates coverage on Helius Medical Tech (NASDAQ:HSDT) with a Buy rating and announces Price Target of $5.
Recap: Helius Medical Tech Q2 Earnings
Helius Medical Tech (NASDAQ:HSDT) reported its Q2 earnings results on Monday, August 15, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Nasdaq Falls Over 100 Points, Marker Therapeutics Shares Spike Higher
U.S. stocks traded mostly lower toward the end of trading, following the release of jobs data
Why Cooper-Standard Is Trading Higher By 70%, Here Are 81 Stocks Moving In Friday’s Mid-Day Session
Gainers
Assure Holdings Corp. (NASDAQ: IONM) shares jumped 88.8% to $3.9650 after jumping around 104% on Thursday.
Dow Drops 150 Points, Crude Oil Rises Over 2%
U.S. stocks traded lower midway through trading, following the release of jobs data
Helius Medical Technologies, Inc. Prices 24M Share Common Stock Offering For Proceeds Of $18M
Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced the pricing of a public offering of (i) 24,000,000
Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday’s Mid-Day Session
Gainers
InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday.
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
Gainers
Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume.